amivantamab: Clinical Trials

7 trials of amivantamab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

4 active not recruiting, 3 recruiting. 7 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	7	Active not recruiting 4, Recruiting 3

Follow amivantamab: new trials by email Literature Review of amivantamab trials Research Report on amivantamab

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer Amivantamab, Pembrolizumab, Carboplatin - Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	Janssen Research & Development, LLC	500	2025-12-03	2026-09-25
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Amivantamab, Cetuximab, Bevacizumab - Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	700	2024-12-12	2026-09-25
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Amivantamab, Cetuximab, 5-fluorouracil - Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	1000	2024-10-18	2026-09-25
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous - Advanced or Metastatic Non-small Cell Lung Cancer	Phase 3	Active not recruiting	Janssen Research & Development, LLC	418	2022-08-05	2026-09-28
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Lazertinib, Amivantamab, Pemetrexed - Carcinoma, Non-Small-Cell Lung	Phase 3	Active not recruiting	Janssen Research & Development, LLC	776	2021-11-17	2026-09-28
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Amivantamab, Pemetrexed, Carboplatin - Carcinoma, Non-Small-Cell Lung	Phase 3	Active not recruiting	Janssen Research & Development, LLC	308	2020-10-13	2026-10-29
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Amivantamab, Osimertinib, Lazertinib - Carcinoma, Non-Small-Cell Lung	Phase 3	Active not recruiting	Janssen Research & Development, LLC	1074	2020-09-30	2026-09-28

Conditions studied

Sponsors

Countries

Results publications

NIH funding